Memantine +/- Raloxifene for Cognitive Preservation After Radiation Therapy to the Brain

The study investigators are testing to see if patients receiving radiation treatment for brain cancer along with raloxifene plus memantidine take longer to develop memory issues. The study will include anyone over the age of 18 who will be treated with radiation for brain cancer.

Trial Details

NCT ID
NCT07470606
Phase
PHASE2
Sponsor
The University of Texas Health Science Center at San Antonio
Status
RECRUITING
Cancer Type
Brain Cancer
Interventions
  • Memantine
  • Raloxifene
Locations (sample)
  • San Antonio, Texas, United States|29.42412,-98.49363

Key Eligibility Criteria

  • Age ≥ 18 years.
  • Ability to provide informed written consent in either English or Spanish.
  • All individuals of childbearing potential must have a negative serum pregnancy test and male and female subjects must agree to use effective means …
  • Patients undergoing radiation therapy to the brain as a part of solid tumor cancer therapy, using intensity modulated radiation therapy (IMRT) or w…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →